Trial Profile
Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Adrenal cancer; Liver metastases; Solid tumours
- Focus Adverse reactions
- 01 Jun 2023 Results assessing 5-year overall survival (OS) rates for patients with metastatic disease treated with this combined-modality therapy, published in the Radiotherapy and Oncology.
- 28 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Jan 2020 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.